Monoclonal Antibodies Partnering Terms and Agreements
Published: Aug 2014 | Publisher: Current Partnering | Pages: 1SUMMARY
The Monoclonal Antibodies Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the monoclonal antibodies partnering deals and agreements entered into by the worlds leading healthcare companies.
TABLE OF CONTENTS
Executive Summary
Chapter 1 Introduction
Chapter 2 Trends in monoclonal antibody dealmaking
2.1. Introduction
2.2. Monoclonal antibody partnering over the years
2.3. Big pharma monoclonal antibody dealmaking activity
2.4. Big biotech monoclonal antibody dealmaking activity
2.5. Most active in monoclonal antibody partnering
2.6. Monoclonal antibody partnering by deal type
2.7. Monoclonal antibody partnering by disease type
2.8. Monoclonal antibody partnering by specific technology type
2.9 Average deal terms for monoclonal antibody
2.9.1 Monoclonal antibody headline values
2.9.2 Monoclonal antibody upfront payments
2.9.3 Monoclonal antibody milestone payments
2.9.4 Monoclonal antibody royalty rates
2.9.10. The anatomy of monoclonal antibody partnering
2.10. The anatomy of a monoclonal antibody deal
2.10.a. Case study 1: ADMA Biologics- Biotest: December 31 2012
2.10.b. Case study 2: Case study 2: Amgen- AstraZeneca: April 2, 2012
Chapter 3 Leading monoclonal antibody deals
3.1. Introduction
3.2. Top monoclonal antibody deals by value
Chapter 4 Big pharma monoclonal antibody deals
4.1. Introduction
4.2. How to use big pharma monoclonal antibody partnering deals
4.3. Big pharma monoclonal antibody partnering company profiles
Abbott
Abbvie
Actavis (previously called Watson)
Allergan
Amgen
Astellas
AstraZeneca
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Chugai Pharmaceutical
CSL
Daiichi Sankyo
Eli Lilly
Fresenius
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Otsuka
Pfizer
Roche
Sanofi
Servier
Shionogi
Takeda
Teva
UCB
Chapter 5 Big biotech monoclonal antibodies deals
5.1. Introduction
5.2. How to use big biotech partnering deals
5.3. Big biotech monoclonal antibody partnering company profiles
Alexion Pharmaceuticals
Biogen Idec
Elan
Emergent BioSolutions
Galapagos
Genmab
Morphosys
Novo Nordisk
PDL BioPharma
Regeneron Pharmaceuticals
Seattle Genetics
Spectrum Pharmaceuticals
Swedish Orphan Biovitrum
Chapter 6 Monoclonal antibody contracts dealmaking directory
6.1. Introduction
6.2. Company A-Z
Abbott Laboratories
Abbvie
ADMA Biologics
Alder Biopharmaceuticals
Alexion Pharmaceuticals
Althea Technologies
Amgen
AstraZeneca
Avecia Biologics
AVEO Pharmaceuticals
Bayer
Bayer Schering Pharma
Biogen Idec
Biotest
Boehringer Ingelheim
Bristol-Myers Squibb
Cell Therapeutics
Centocor Ortho Biotech
ContraFect
Crucell
Cytodyn
Elan
Eli Lilly
Facet Biotechnology
Fujifilm Diosynth Biotechnologies
GE Healthcare
Genentech
Genzyme
Gilead Sciences
GlaxoSmithKline
GlycArt
Green Cross
ImmunoCellular Therapeutics
ImmunoGen
Intrexon
Janssen Pharmaceutica NV
Johnson & Johnson
KaloBios Pharmaceuticals
Kyowa Hakko Kirin
Lonza
Lpath
Macrogenics
Massachusetts Biologic Laboratories
Medarex
Merck and Co
Merrimack Pharmaceuticals
Micromet
Millennium
MorphoSys
Novartis
Novo Nordisk
Orbimed Advisors
Ortho-McNeil
PDL BioPharma
Peregrine Pharmaceuticals
Pfizer
PharmAthene
Progenics Pharmaceuticals
Receptos
Regeneron Pharmaceuticals
Repligen
RIT Oncology
Roche
Sanofi-Aventis
Sanofi-Pasteur
Seattle Genetics
Servier
Sicor Italy
Spectrum Pharmaceuticals
Stason Pharmaceuticals
Synthetic Biologics
Takeda Pharmaceutical
Targepeutics
Trellis Bioscience
TrovaGene
TTFactor
UCB
Ultragenyx Pharmaceuticals
University of Texas
Wyeth
Xencor
Xoma
ZymoGenetics
6.3. By deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Contract service
Co-promotion
Cross-licensing
Development
Equity purchase
Evaluation
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Supply
Termination
6.4. By stage of development
Discovery
Marketed
Phase I
Phase II
Phase III
Preclinical
6.5. By therapy indication
Cardiovascular
Central Nervous System
Dermatology
Gastrointestinal
Gynaecology
Hematology
Hospital Care
Immunology
Infectives
Metabolic
Musculoskeletal
Oncology
Ophthalmics
Orphan disease
Psychiatry
Respiratory
Chapter 7 Monoclonal antibody deals by individual technology type
Chapter 8 Monoclonal antibody partnering resource center
8.1. Online monoclonal antibody partnering
8.2. Monoclonal antibody partnering events
8.3. Further reading on monoclonal antibody dealmaking
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from Current Partnering
Order Form Technology reports
Order Form Upgrades to subscription access products
See accompanying volume for:
Appendices
Introduction
Appendix 1 Directory of monoclonal antibody deals by company A-Z 2009-2014
Appendix 2 Directory of monoclonal antibody deals by stage of development 2009-2014
Appendix 3 Directory of monoclonal antibody deals by deal type 2009-2014
Appendix 4 Directory of monoclonal antibody deals by therapy area 2009-2014
Appendix 5 Monoclonal antibody partnering resource center
Online monoclonal antibody partnering
Monoclonal antibody partnering events
Further reading on monoclonal antibody dealmaking
Table of figures
Figure 1: Monoclonal antibody partnering since 2009
Figure 2: Big pharma top 50 monoclonal antibody deals 2009 to 2014
Figure 3: Big pharma monoclonal antibody deal frequency 2009 to 2014
Figure 4: Big biotech monoclonal antibody deals 2009 to 2014
Figure 5: Big biotech monoclonal antibody deal frequency 2009 to 2014
Figure 6: Active monoclonal antibody dealmaking activity 2009 to 2014
Figure 7: Monoclonal antibody partnering by deal type since 2009
Figure 8: Monoclonal antibody partnering by disease type since 2009
Figure 9: Monoclonal antibody partnering by oncology target since 2009
Figure 10: Monoclonal antibody partnering by technology type since 2009
Figure 11: Monoclonal antibody deals with a headline value
Figure 12: Monoclonal antibody deal headline value distribution, US$million 2009-2014 Discovery stage
Figure 13: Monoclonal antibody deal headline value distribution, US$million 2009-2014 preclinical stage
Figure 14: Monoclonal antibody deal headline value distribution, US$million 2009-2014 phase I stage
Figure 15: Monoclonal antibody deal headline value distribution, US$million 2009-2014 phase II stage
Figure 16: Monoclonal antibody deal headline value distribution, US$million 2009-2014 phase III stage
Figure 17: Monoclonal antibody deal headline value distribution, US$million 2009-2014 regulatory stage
Figure 18: Monoclonal antibody deal headline value distribution, US$million 2009-2014 marketed stage
Figure 19: Summary median headline value by stage of development, 2009-2014
Figure 20: Monoclonal antibody deals with an upfront value
Figure 21: Monoclonal antibody deal upfront value distribution, US$million 2009-2014 discovery stage
Figure 22: Monoclonal antibody deal upfront value distribution, US$million 2009-2014 preclinical stage
Figure 23: Monoclonal antibody deal upfront value distribution, US$million 2009-2014 phase I stage
Figure 24: Monoclonal antibody deal upfront value distribution, US$million 2009-2014 phase II stage
Figure 25: Monoclonal antibody deal upfront value distribution, US$million 2009-2014 phase III stage
Figure 26: Monoclonal antibody deal upfront value distribution, US$million 2009-2014 regulatory stage
Figure 27: Monoclonal antibody deal upfront value distribution, US$million 2009-2014 marketed stage
Figure 28: Summary median headline value by stage of development, 2009-2014
Figure 29: Monoclonal antibody deals with a milestone value
Figure 30: Monoclonal antibody deal milestone value distribution, US$million 2009-2014 discovery stage
Figure 31: Monoclonal antibody deal milestone value distribution, US$million 2009-2014 preclinical stage
Figure 32: Monoclonal antibody deal milestone value distribution, US$million 2009-2014 phase I stage
Figure 33: Monoclonal antibody deal milestone value distribution, US$million 2009-2014 phase II stage
Figure 34: Monoclonal antibody deal milestone value distribution, US$million 2009-2014 phase III stage
Figure 35: Monoclonal antibody deal milestone value distribution, US$million 2009-2014 regulatory stage
Figure 36: Monoclonal antibody deal milestone value distribution, US$million 2009-2014 marketed stage
Figure 37: Monoclonal antibody deals with royalty rates
Figure 38: Monoclonal antibody deal royalty rate value distribution, US$million 2009-2014 discovery stage
Figure 39: Monoclonal antibody deal royalty rate value distribution, US$million 2009-2014 preclinical stage
Figure 40: Monoclonal antibody deal royalty rate value distribution, US$million 2009-2014 phase I stage
Figure 41: Monoclonal antibody deal royalty rate value distribution, US$million 2009-2014 phase II stage
Figure 42: Monoclonal antibody deal royalty rate value distribution, US$million 2009-2014 phase III stage
Figure 43: Monoclonal antibody deal royalty rate value distribution, US$million 2009-2014 regulatory stage
Figure 44: Monoclonal antibody deal royalty rate value distribution, US$million 2009-2014 marketed stage
Figure 45: Summary median headline value by stage of development, 2009-2014
Figure 46: Components of the typical monoclonal antibody deal structure
Figure 47: Top monoclonal antibody deals by value since 2009
Figure 48: Online partnering resources
Figure 49: Forthcoming partnering events
Figure 49: Forthcoming partnering events
Chapter 1 Introduction
Chapter 2 Trends in monoclonal antibody dealmaking
2.1. Introduction
2.2. Monoclonal antibody partnering over the years
2.3. Big pharma monoclonal antibody dealmaking activity
2.4. Big biotech monoclonal antibody dealmaking activity
2.5. Most active in monoclonal antibody partnering
2.6. Monoclonal antibody partnering by deal type
2.7. Monoclonal antibody partnering by disease type
2.8. Monoclonal antibody partnering by specific technology type
2.9 Average deal terms for monoclonal antibody
2.9.1 Monoclonal antibody headline values
2.9.2 Monoclonal antibody upfront payments
2.9.3 Monoclonal antibody milestone payments
2.9.4 Monoclonal antibody royalty rates
2.9.10. The anatomy of monoclonal antibody partnering
2.10. The anatomy of a monoclonal antibody deal
2.10.a. Case study 1: ADMA Biologics- Biotest: December 31 2012
2.10.b. Case study 2: Case study 2: Amgen- AstraZeneca: April 2, 2012
Chapter 3 Leading monoclonal antibody deals
3.1. Introduction
3.2. Top monoclonal antibody deals by value
Chapter 4 Big pharma monoclonal antibody deals
4.1. Introduction
4.2. How to use big pharma monoclonal antibody partnering deals
4.3. Big pharma monoclonal antibody partnering company profiles
Abbott
Abbvie
Actavis (previously called Watson)
Allergan
Amgen
Astellas
AstraZeneca
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Chugai Pharmaceutical
CSL
Daiichi Sankyo
Eli Lilly
Fresenius
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Otsuka
Pfizer
Roche
Sanofi
Servier
Shionogi
Takeda
Teva
UCB
Chapter 5 Big biotech monoclonal antibodies deals
5.1. Introduction
5.2. How to use big biotech partnering deals
5.3. Big biotech monoclonal antibody partnering company profiles
Alexion Pharmaceuticals
Biogen Idec
Elan
Emergent BioSolutions
Galapagos
Genmab
Morphosys
Novo Nordisk
PDL BioPharma
Regeneron Pharmaceuticals
Seattle Genetics
Spectrum Pharmaceuticals
Swedish Orphan Biovitrum
Chapter 6 Monoclonal antibody contracts dealmaking directory
6.1. Introduction
6.2. Company A-Z
Abbott Laboratories
Abbvie
ADMA Biologics
Alder Biopharmaceuticals
Alexion Pharmaceuticals
Althea Technologies
Amgen
AstraZeneca
Avecia Biologics
AVEO Pharmaceuticals
Bayer
Bayer Schering Pharma
Biogen Idec
Biotest
Boehringer Ingelheim
Bristol-Myers Squibb
Cell Therapeutics
Centocor Ortho Biotech
ContraFect
Crucell
Cytodyn
Elan
Eli Lilly
Facet Biotechnology
Fujifilm Diosynth Biotechnologies
GE Healthcare
Genentech
Genzyme
Gilead Sciences
GlaxoSmithKline
GlycArt
Green Cross
ImmunoCellular Therapeutics
ImmunoGen
Intrexon
Janssen Pharmaceutica NV
Johnson & Johnson
KaloBios Pharmaceuticals
Kyowa Hakko Kirin
Lonza
Lpath
Macrogenics
Massachusetts Biologic Laboratories
Medarex
Merck and Co
Merrimack Pharmaceuticals
Micromet
Millennium
MorphoSys
Novartis
Novo Nordisk
Orbimed Advisors
Ortho-McNeil
PDL BioPharma
Peregrine Pharmaceuticals
Pfizer
PharmAthene
Progenics Pharmaceuticals
Receptos
Regeneron Pharmaceuticals
Repligen
RIT Oncology
Roche
Sanofi-Aventis
Sanofi-Pasteur
Seattle Genetics
Servier
Sicor Italy
Spectrum Pharmaceuticals
Stason Pharmaceuticals
Synthetic Biologics
Takeda Pharmaceutical
Targepeutics
Trellis Bioscience
TrovaGene
TTFactor
UCB
Ultragenyx Pharmaceuticals
University of Texas
Wyeth
Xencor
Xoma
ZymoGenetics
6.3. By deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Contract service
Co-promotion
Cross-licensing
Development
Equity purchase
Evaluation
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Supply
Termination
6.4. By stage of development
Discovery
Marketed
Phase I
Phase II
Phase III
Preclinical
6.5. By therapy indication
Cardiovascular
Central Nervous System
Dermatology
Gastrointestinal
Gynaecology
Hematology
Hospital Care
Immunology
Infectives
Metabolic
Musculoskeletal
Oncology
Ophthalmics
Orphan disease
Psychiatry
Respiratory
Chapter 7 Monoclonal antibody deals by individual technology type
Chapter 8 Monoclonal antibody partnering resource center
8.1. Online monoclonal antibody partnering
8.2. Monoclonal antibody partnering events
8.3. Further reading on monoclonal antibody dealmaking
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from Current Partnering
Order Form Technology reports
Order Form Upgrades to subscription access products
See accompanying volume for:
Appendices
Introduction
Appendix 1 Directory of monoclonal antibody deals by company A-Z 2009-2014
Appendix 2 Directory of monoclonal antibody deals by stage of development 2009-2014
Appendix 3 Directory of monoclonal antibody deals by deal type 2009-2014
Appendix 4 Directory of monoclonal antibody deals by therapy area 2009-2014
Appendix 5 Monoclonal antibody partnering resource center
Online monoclonal antibody partnering
Monoclonal antibody partnering events
Further reading on monoclonal antibody dealmaking
Table of figures
Figure 1: Monoclonal antibody partnering since 2009
Figure 2: Big pharma top 50 monoclonal antibody deals 2009 to 2014
Figure 3: Big pharma monoclonal antibody deal frequency 2009 to 2014
Figure 4: Big biotech monoclonal antibody deals 2009 to 2014
Figure 5: Big biotech monoclonal antibody deal frequency 2009 to 2014
Figure 6: Active monoclonal antibody dealmaking activity 2009 to 2014
Figure 7: Monoclonal antibody partnering by deal type since 2009
Figure 8: Monoclonal antibody partnering by disease type since 2009
Figure 9: Monoclonal antibody partnering by oncology target since 2009
Figure 10: Monoclonal antibody partnering by technology type since 2009
Figure 11: Monoclonal antibody deals with a headline value
Figure 12: Monoclonal antibody deal headline value distribution, US$million 2009-2014 Discovery stage
Figure 13: Monoclonal antibody deal headline value distribution, US$million 2009-2014 preclinical stage
Figure 14: Monoclonal antibody deal headline value distribution, US$million 2009-2014 phase I stage
Figure 15: Monoclonal antibody deal headline value distribution, US$million 2009-2014 phase II stage
Figure 16: Monoclonal antibody deal headline value distribution, US$million 2009-2014 phase III stage
Figure 17: Monoclonal antibody deal headline value distribution, US$million 2009-2014 regulatory stage
Figure 18: Monoclonal antibody deal headline value distribution, US$million 2009-2014 marketed stage
Figure 19: Summary median headline value by stage of development, 2009-2014
Figure 20: Monoclonal antibody deals with an upfront value
Figure 21: Monoclonal antibody deal upfront value distribution, US$million 2009-2014 discovery stage
Figure 22: Monoclonal antibody deal upfront value distribution, US$million 2009-2014 preclinical stage
Figure 23: Monoclonal antibody deal upfront value distribution, US$million 2009-2014 phase I stage
Figure 24: Monoclonal antibody deal upfront value distribution, US$million 2009-2014 phase II stage
Figure 25: Monoclonal antibody deal upfront value distribution, US$million 2009-2014 phase III stage
Figure 26: Monoclonal antibody deal upfront value distribution, US$million 2009-2014 regulatory stage
Figure 27: Monoclonal antibody deal upfront value distribution, US$million 2009-2014 marketed stage
Figure 28: Summary median headline value by stage of development, 2009-2014
Figure 29: Monoclonal antibody deals with a milestone value
Figure 30: Monoclonal antibody deal milestone value distribution, US$million 2009-2014 discovery stage
Figure 31: Monoclonal antibody deal milestone value distribution, US$million 2009-2014 preclinical stage
Figure 32: Monoclonal antibody deal milestone value distribution, US$million 2009-2014 phase I stage
Figure 33: Monoclonal antibody deal milestone value distribution, US$million 2009-2014 phase II stage
Figure 34: Monoclonal antibody deal milestone value distribution, US$million 2009-2014 phase III stage
Figure 35: Monoclonal antibody deal milestone value distribution, US$million 2009-2014 regulatory stage
Figure 36: Monoclonal antibody deal milestone value distribution, US$million 2009-2014 marketed stage
Figure 37: Monoclonal antibody deals with royalty rates
Figure 38: Monoclonal antibody deal royalty rate value distribution, US$million 2009-2014 discovery stage
Figure 39: Monoclonal antibody deal royalty rate value distribution, US$million 2009-2014 preclinical stage
Figure 40: Monoclonal antibody deal royalty rate value distribution, US$million 2009-2014 phase I stage
Figure 41: Monoclonal antibody deal royalty rate value distribution, US$million 2009-2014 phase II stage
Figure 42: Monoclonal antibody deal royalty rate value distribution, US$million 2009-2014 phase III stage
Figure 43: Monoclonal antibody deal royalty rate value distribution, US$million 2009-2014 regulatory stage
Figure 44: Monoclonal antibody deal royalty rate value distribution, US$million 2009-2014 marketed stage
Figure 45: Summary median headline value by stage of development, 2009-2014
Figure 46: Components of the typical monoclonal antibody deal structure
Figure 47: Top monoclonal antibody deals by value since 2009
Figure 48: Online partnering resources
Figure 49: Forthcoming partnering events
Figure 49: Forthcoming partnering events
$2,995
My Basket
 | Co-development Terms & Agreements in Pharma, Biotech and Diagnostics | $2,995 |
| Abbvie Partnering 2009-2014 | $995 |
| Abbott Partnering 2009-2014 | $995 |
| Monoclonal Antibodies Partnering Terms and Agreements | $2,995 |
| TOTAL | $7,980 | |
| Empty Cart | ||
| ||
Need Help?
Unsure which report to purchase or have a query regarding a report, please contact us and we'll be glad to help.
Contact our Report Store Team
Email us or call
+44 (0)1904 435190 Europe
+1 (813) 971.8273 US
- Most Viewed